BRPI0720569B8 - compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária - Google Patents

compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária

Info

Publication number
BRPI0720569B8
BRPI0720569B8 BRPI0720569A BRPI0720569A BRPI0720569B8 BR PI0720569 B8 BRPI0720569 B8 BR PI0720569B8 BR PI0720569 A BRPI0720569 A BR PI0720569A BR PI0720569 A BRPI0720569 A BR PI0720569A BR PI0720569 B8 BRPI0720569 B8 BR PI0720569B8
Authority
BR
Brazil
Prior art keywords
compounds
bacterial
viral
treatment
substituted tetracycline
Prior art date
Application number
BRPI0720569A
Other languages
English (en)
Inventor
Verma Atul
Bhatia Beena
Assefa Haregewein
Pan Jingwen
Berniac Joel
Honeyman Laura
Grier Mark
Nelson Mark
Ismail Mohamed
K Kim Oak
Abato Paul
Bowser Todd
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of BRPI0720569A2 publication Critical patent/BRPI0720569A2/pt
Publication of BRPI0720569B1 publication Critical patent/BRPI0720569B1/pt
Publication of BRPI0720569B8 publication Critical patent/BRPI0720569B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

compostos de tetraciclina substituída. a presente invenção se refere, pelo menos em parte, a novos compostos de tetraciclina substituída. esses compostos de tetraciclina podem ser usados para tratar diversos estados que respondam aos compostos de tetraciclina, tal como infecções bacterianas e neoplasmas.
BRPI0720569A 2006-12-21 2007-12-21 compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária BRPI0720569B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US87631306P 2006-12-21 2006-12-21
US60/876.313 2006-12-21
US94300307P 2007-06-08 2007-06-08
US60/943.003 2007-06-08
PCT/US2007/026178 WO2008079339A2 (en) 2006-12-21 2007-12-21 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections

Publications (3)

Publication Number Publication Date
BRPI0720569A2 BRPI0720569A2 (pt) 2014-02-04
BRPI0720569B1 BRPI0720569B1 (pt) 2020-10-13
BRPI0720569B8 true BRPI0720569B8 (pt) 2021-05-25

Family

ID=39495878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720569A BRPI0720569B8 (pt) 2006-12-21 2007-12-21 compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária

Country Status (16)

Country Link
US (4) US8318706B2 (pt)
EP (6) EP2109602B1 (pt)
JP (8) JP5583411B2 (pt)
KR (1) KR101538175B1 (pt)
AU (1) AU2007338747B2 (pt)
BR (1) BRPI0720569B8 (pt)
CA (3) CA2925939C (pt)
DK (1) DK2109602T3 (pt)
ES (2) ES2463457T3 (pt)
HK (2) HK1135101A1 (pt)
IL (4) IL270446B2 (pt)
MX (1) MX2009006846A (pt)
PL (1) PL2109602T3 (pt)
PT (1) PT2109602E (pt)
SI (1) SI2109602T1 (pt)
WO (1) WO2008079339A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
US8318706B2 (en) 2006-12-21 2012-11-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
PT2120963T (pt) 2006-12-21 2018-12-17 Paratek Pharm Innc Compostos tetraciclina substituídos para tratamento de distúrbios inflamatórios da pele
ATE555079T1 (de) * 2007-07-06 2012-05-15 Paratek Pharm Innc Verfahren zur synthese von 9-substituiertem minocyclin
CN102015602A (zh) 2008-03-05 2011-04-13 帕拉特克药品公司 米诺环素化合物及其使用方法
AU2009236631A1 (en) * 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
KR20110081197A (ko) * 2008-09-19 2011-07-13 파라테크 파마슈티컬스, 인크. 류마티스 관절염의 치료를 위한 테트라시클린 화합물 및 관련된 치료 방법
CN102459153A (zh) 2009-05-08 2012-05-16 四相制药公司 四环素类化合物
CN105622496B (zh) * 2009-08-28 2019-03-05 四相制药公司 四环素类化合物
US8754054B2 (en) 2010-07-09 2014-06-17 Albany Molecular Research, Inc. Antibacterial compounds, methods of making them, and uses thereof
EP3574908A1 (en) * 2011-05-12 2019-12-04 Paratek Pharmaceuticals, Inc. Crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2carboxylic acid amide and methods of using the same
DK2738156T3 (en) 2011-07-26 2018-03-26 Kbp Biosciences Usa Inc 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS
WO2013072703A1 (en) * 2011-11-18 2013-05-23 Redx Pharma Limited Antibacterial drug derivatives
CN103387512B (zh) * 2012-05-08 2016-08-31 成都睿智化学研究有限公司 一种米诺环素的制备方法及其中间体
CA2873412A1 (en) * 2012-05-14 2013-11-21 Paratek Pharmaceuticals, Inc. Methods of using (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide
JP6522498B2 (ja) * 2012-05-30 2019-05-29 パラテック ファーマシューティカルズ インコーポレイテッド ７−二置換フェニルテトラサイクリン誘導体
CA2878462A1 (en) * 2012-07-13 2014-01-16 Paratek Pharmaceuticals, Inc. Tetracycline compounds for treating neurodegenerative disorders
PT2890673T (pt) 2012-08-31 2019-02-19 Tetraphase Pharmaceuticals Inc Compostos de tetraciclina
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
DE102015013086A1 (de) 2015-10-01 2017-04-06 Jutta Regina Giller Attika für Gebäude
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
SG11201903846TA (en) 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
CA3070663A1 (en) 2017-07-21 2019-01-24 Almirall, Llc Treatment of non-inflammatory lesions
KR102011721B1 (ko) * 2017-11-28 2019-08-19 고려대학교 산학협력단 포도상구균의 생육을 억제하는 한천 유래 올리고당의 용도
CN115380022A (zh) * 2018-04-06 2022-11-22 帕拉特克药品公司 萨瑞环素盐酸盐的制造方法
CN109970590A (zh) * 2018-12-20 2019-07-05 深圳市祥根生物科技有限公司 一种7-氨基米诺环素的制备方法
CN109574868B (zh) * 2018-12-28 2021-11-16 天津阿尔塔科技有限公司 一种四环素类及其差向异构体氘代内标物的制备方法
WO2021231314A1 (en) * 2020-05-11 2021-11-18 Paratek Pharmaceuticals Inc. Methods of treating covid-19 using tetracycline compounds
CN111574392A (zh) * 2020-05-27 2020-08-25 浙江工业大学 一种6-去甲基-6-脱水四环素的制备方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34656A (en) 1862-03-11 Improvement in liquids for exciting galvanic batteries
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3047617A (en) * 1959-05-18 1962-07-31 Pfizer & Co C Alkanoic acid esters of 5-hydroxytetracycline and process for preparation
GB921252A (en) 1960-03-09 1963-03-20 Erba Carlo Spa New tetracycline derivatives
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
GB1108310A (en) 1964-04-30 1968-04-03 Pfizer & Co C Derivatives of 6-methylene-tetracycline and process for their preparation
US3345379A (en) * 1965-02-26 1967-10-03 American Cyanamid Co 7-imidomethyl-6-demethyl-6-deoxytetracyclines
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
US3304227A (en) 1965-07-15 1967-02-14 Loyal E Loveless Antibiotic-containing animal feed
NL6607516A (pt) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
CA999855A (en) * 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2527568A1 (de) 1974-06-25 1976-01-15 Farmaceutici Italia Verfahren zur herstellung von alkyltetracyclinen und neue tetracyclinderivate
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US5064821A (en) 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US5589470A (en) 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US4935412A (en) 1983-12-29 1990-06-19 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
US4704383A (en) 1983-12-29 1987-11-03 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same
USRE34656E (en) 1983-12-29 1994-07-05 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4806372A (en) 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
JP3016587B2 (ja) 1989-12-04 2000-03-06 ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 非ステロイド抗炎症剤及びテトラサイクリンの配合
US5308839A (en) 1989-12-04 1994-05-03 The Research Foundation Of State University Of New York Composition comprising non-steroidal anti-inflammatory agent tenidap and effectively non-antibacterial tetracycline
DE4031168A1 (de) 1990-10-03 1992-04-16 Degussa Keramischer werkstoff zum verblenden von metallischem zahnersatz
US5770588A (en) 1991-02-11 1998-06-23 The Research Foundation Of State University Of New York Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
US5231017A (en) 1991-05-17 1993-07-27 Solvay Enzymes, Inc. Process for producing ethanol
US6756365B2 (en) 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5258371A (en) 1992-05-29 1993-11-02 Kuraray Co., Ltd. Method to reduce connective tissue destruction
US6043225A (en) 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
EP0599397B1 (en) 1992-11-17 1996-08-28 The Research Foundation Of State University Of New York Tetracyclines including non-antimicrobial chemically-modified tetracyclines inhibit excessive collagen crosslinking during diabetes
US6043231A (en) 1993-03-02 2000-03-28 The Research Foundation Of State Univ. Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5523297A (en) 1993-03-02 1996-06-04 The Research Foundation Of State University Of New York Inhibition of excessive phospholipase A2 activity and/or production by non-antimicrobial tetracyclines
US5668122A (en) 1993-07-28 1997-09-16 Fife; Rose S. Method to treat cancer with tetracyclines
WO1995022529A1 (en) 1994-02-17 1995-08-24 Pfizer Inc. 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
NZ304095A (en) 1995-05-03 1998-10-28 Pfizer 9-(substituted acylamino) tetracyclic derivatives and medicaments
US5834449A (en) 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
US5827840A (en) 1996-08-01 1998-10-27 The Research Foundation Of State University Of New York Promotion of wound healing by chemically-modified tetracyclines
US5789395A (en) 1996-08-30 1998-08-04 The Research Foundation Of State University Of New York Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
US5919774A (en) 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
US5837696A (en) 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US5773430A (en) 1997-03-13 1998-06-30 Research Foundation Of State University Of New York Serine proteinase inhibitory activity by hydrophobic tetracycline
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US20020123637A1 (en) 1998-01-23 2002-09-05 Stuart B. Levy Pharmaceutically active compounds and methods of use thereof
US6277061B1 (en) 1998-03-31 2001-08-21 The Research Foundation Of State University Of New York Method of inhibiting membrane-type matrix metalloproteinase
US6015804A (en) 1998-09-11 2000-01-18 The Research Foundation Of State University Of New York Method of using tetracycline compounds to enhance interleukin-10 production
US5977091A (en) 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US5998390A (en) 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
US6256365B1 (en) 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
DK1240133T3 (da) 1999-09-14 2006-08-21 Tufts College Fremgangsmåde til fremstilling af substituerede tetracycliner med overgangsmetalbaserede kemiske metoder
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6231894B1 (en) 1999-10-21 2001-05-15 Duke University Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
WO2001052858A1 (en) 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
JP2004505012A (ja) 2000-03-31 2004-02-19 トラスティーズ・オブ・タフツ・カレッジ ７−および９−カルバメート、尿素、チオ尿素、チオカルバメート、およびヘテロアリール−アミノ置換テトラサイクリン化合物
DE60102815D1 (de) 2000-05-15 2004-05-19 Paratek Pharm Innc 7-substituierte kondensierte ring-tetrazyclin- verbindungen
KR100518046B1 (ko) 2000-05-19 2005-10-04 아밀린 파마슈티칼스, 인크. Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
US20040224927A1 (en) 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
US20020128238A1 (en) 2000-06-16 2002-09-12 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20050143353A1 (en) 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
US6846939B2 (en) 2000-07-07 2005-01-25 Paratek Pharmaceuticals, Inc. 9-substituted minocycline compounds
DE60144375D1 (de) 2000-07-07 2011-05-19 Trustees Of Tufts College Medford 7-, 8- und 9-substitutierte tetracyclinverbindungen
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
HUP0301163A3 (en) 2000-07-07 2008-08-28 Tufts College 7-substituted tetracycline dervatives, pharmaceutical compositions containing them and their use
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
EP1241160A1 (en) 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
AU2002250331A1 (en) 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
CA2457234A1 (en) 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
WO2002072031A2 (en) * 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
DE60235083D1 (de) * 2001-04-24 2010-03-04 Paratek Pharm Innc Substituierte tetracyclin-verbindungen zur behandlung von malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
AU2002365120A1 (en) 2001-08-02 2003-07-15 Paratek Pharmaceuticals, Inc. Medicaments
US20030069721A1 (en) 2001-09-10 2003-04-10 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
EP2311798A1 (en) * 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EA200802365A1 (ru) * 2002-03-08 2009-08-28 Паратек Фармасьютикалс, Инк. Аминометилзамещенные тетрациклиновые соединения
IL164180A0 (en) * 2002-03-21 2005-12-18 Paratek Pharm Innc Substituted tetracycline compounds
EP1494681A4 (en) 2002-04-16 2008-08-06 Collagenex Pharm Inc PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
EP1556007A4 (en) * 2002-10-24 2008-12-17 Paratek Pharm Innc SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
EP1562608A4 (en) * 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
WO2004064728A2 (en) 2003-01-16 2004-08-05 Paratek Pharmaceuticals, Inc. Use of specific tetracycline compounds in therapy
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
JP4738333B2 (ja) * 2003-07-09 2011-08-03 パラテック ファーマシューティカルズ インコーポレイテッド ９−アミノメチルテトラサイクリン化合物のプロドラッグ
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2553510C (en) 2004-01-15 2012-09-25 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
WO2005082860A1 (en) * 2004-02-27 2005-09-09 National Research Council Of Canada Tetracyclines and their use as calpain inhibitors
KR101336462B1 (ko) * 2004-05-21 2013-12-04 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 테트라사이클린 및 이의 유사체의 합성
EP2949644A3 (en) 2004-10-25 2016-04-20 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
US20070015738A1 (en) * 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
WO2007087416A2 (en) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CA2652346A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
US8318706B2 (en) * 2006-12-21 2012-11-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
JP2010523684A (ja) * 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
CA2688662A1 (en) 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
ATE555079T1 (de) 2007-07-06 2012-05-15 Paratek Pharm Innc Verfahren zur synthese von 9-substituiertem minocyclin
KR20110081197A (ko) * 2008-09-19 2011-07-13 파라테크 파마슈티컬스, 인크. 류마티스 관절염의 치료를 위한 테트라시클린 화합물 및 관련된 치료 방법

Also Published As

Publication number Publication date
IL270446B1 (en) 2023-06-01
IL250858A0 (en) 2017-04-30
US20210395189A1 (en) 2021-12-23
JP2010513527A (ja) 2010-04-30
EP3812372A3 (en) 2021-06-30
EP2452935A3 (en) 2012-08-29
EP2109602B1 (en) 2014-02-12
US8318706B2 (en) 2012-11-27
CA3051994A1 (en) 2008-07-03
EP3045449A1 (en) 2016-07-20
US20130102779A1 (en) 2013-04-25
JP2015205939A (ja) 2015-11-19
EP2455367B1 (en) 2015-12-16
IL302749A (en) 2023-07-01
JP6061897B2 (ja) 2017-01-18
KR101538175B1 (ko) 2015-07-20
CA2925939C (en) 2019-10-01
JP2018039846A (ja) 2018-03-15
JP2021063137A (ja) 2021-04-22
US20160046561A1 (en) 2016-02-18
DK2109602T3 (da) 2014-05-19
PL2109602T3 (pl) 2014-09-30
CA2925939A1 (en) 2008-07-03
JP2011093914A (ja) 2011-05-12
EP2450347A1 (en) 2012-05-09
AU2007338747B2 (en) 2013-12-19
JP2014167027A (ja) 2014-09-11
US9012433B2 (en) 2015-04-21
MX2009006846A (es) 2009-08-20
CA2673466A1 (en) 2008-07-03
ES2548261T3 (es) 2015-10-15
KR20090098986A (ko) 2009-09-18
CA2673466C (en) 2016-06-14
JP2024009235A (ja) 2024-01-19
EP3812372A2 (en) 2021-04-28
WO2008079339A2 (en) 2008-07-03
JP2019081802A (ja) 2019-05-30
SI2109602T1 (sl) 2014-06-30
EP2450347B1 (en) 2015-06-24
PT2109602E (pt) 2014-05-23
AU2007338747A1 (en) 2008-07-03
ES2463457T3 (es) 2014-05-28
IL250858B (en) 2019-11-28
EP2455367A1 (en) 2012-05-23
WO2008079339A3 (en) 2008-12-18
HK1135101A1 (en) 2010-05-28
IL270446B2 (en) 2023-10-01
HK1170218A1 (en) 2013-02-22
BRPI0720569A2 (pt) 2014-02-04
IL270446A (pt) 2019-12-31
US20100305072A1 (en) 2010-12-02
JP5583411B2 (ja) 2014-09-03
BRPI0720569B1 (pt) 2020-10-13
EP2109602A2 (en) 2009-10-21
EP2452935A2 (en) 2012-05-16
IL234755A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
BRPI0720569B8 (pt) compostos de tetraciclina substituída e uso dos ditos compostos para o tratamento de uma infecção bacteriana, viral ou parasitária
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
BR112015022861A8 (pt) inibidores de bromodomínio
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
WO2005072826A3 (en) Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
EA201791850A1 (ru) Борсодержащие малые молекулы
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
CL2008001367A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion bacteriana.
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BR112014000542A2 (pt) composições de peroxidase eosinofílica e métodos de uso das mesmas
IN2014CN00572A (pt)
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
CR20230100A (es) Compuestos fosfolípidos y usos de los mismos
BR112014012983A2 (pt) derivados de pirrol
WO2010052575A3 (en) Ngna compositions and methods of use
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
BR112015021001A2 (pt) compostos antivirais
ATE533496T1 (de) Azithromycin zur behandlung von knotiger akne

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/12/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF